Prednisolone acetate ophthalmic suspension 1% is a sterile, topical anti-inflammatory agent for ophthalmic use and is ...

Johnson & Johnson has announced the submission of an extension of indication application to the European Medicines Agency (EMA) seeking approval of Akeega (niraparib/abiraterone acetate) with ...

Prednisolone acetate ophthalmic suspension, USP 1% is a sterile, topical anti-inflammatory agent for ophthalmic use and is indicated for treating steroid-responsive ocular inflammation.

Amneal plans to launch the product in the third quarter of 2025. According to IQVIA, U.S. annual sales for prednisolone acetate ophthalmic suspension for the 12 months ended April 2025 were about ...

The most commonly reported adverse reactions for prednisolone acetate ophthalmic suspension in clinical studies were elevation of intraocular pressure (IOP) with possible development of glaucoma and ...

Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceutical ...

Key complex product approval in the Affordable Medicines segment this year Commercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal ...

Detailed price information for Amneal Pharmaceuticals Inc (AMRX-Q) from The Globe and Mail including charting and trades.

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension Amneal Pharmaceuticals LLC - (GLOBE NEWSWIRE) Jun 12, 2025 ...

These findings support adding niraparib to abiraterone acetate plus prednisone “as a new treatment option” in patients with HRR alterations, said Study Chief Gerhardt Attard, MD, PhD, chair of ...